Trial Profile

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary) ; Volrustomig (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms eVOLVE-01
Sponsors AstraZeneca; AstraZeneca AB

26 Aug 2026 Status changed from recruiting to active, no longer recruiting.
20 Oct 2025 Planned End Date changed from 30 Jun 2027 to 30 Jul 2027.
20 Oct 2025 Planned primary completion date changed from 30 Jun 2027 to 30 Jul 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com